On this page
What happened
On July 17, 2026, FDA reported that CDC had declared the Salmonella outbreak associated with MOGO moringa powder capsules over and that its investigation was complete. The update recorded 34 illnesses, 11 hospitalizations among people with available information, and no reported deaths. It identified recalled lots 15525AA and 00926AA. These are findings about named products and a specific outbreak, rather than evidence about moringa’s effects on memory or attention.
Why it matters
The investigation combined interviews, supply-chain tracing, inspections and product testing. Opened capsule containers collected by several state health departments contained the outbreak strain. FDA traced the manufacturer’s moringa powder to India and described increased screening of imported powder. The important distinction for botanical-supplement buyers is between an ingredient’s proposed biological activity and the quality of the product containing it: the former cannot rule out contamination in the latter.
Scope and limitations
An outbreak closeout does not make recalled stock suitable for use. FDA said the long shelf life meant affected bottles could still be in homes; its notice instructs consumers to discard the named lots and clean surfaces or containers they touched. The investigation neither measured cognitive outcomes nor established contamination across every moringa product. Readers should use the official product and lot identifiers, rather than extend this recall to unrelated brands or assume it describes availability in Turkey.
This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.
Sources
- Outbreak Investigation of Salmonella: Moringa Leaf Powder (May 2026) — U.S. Food and Drug Administration ·
Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.
← All news